GlassScriptPhysician profile
Alison Boudreaux
NPI 1093782120
$39,375.93
in general payments reported to CMS, 2019-2025
37 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,488 · 2020: $1,145 · 2021: $12K · 2022: $6,798 · 2023: $9,505 · 2024: $5,516 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,725 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,087 · Travel and Lodging: $1,130 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,725.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,086.54 |
| Travel and Lodging | $1,130.16 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,950.42 | 2019-2023 | |
| Abbvie INC. | $10,897.90 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $1,307.83 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $1,234.04 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $985.33 | 2019-2025 | |
| Pfizer INC. | $933.31 | 2019-2025 | |
| Janssen Biotech, INC. | $695.83 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $686.93 | 2019-2025 | Jublia, Duobrii, Arazlo |
| Leo Pharma INC. | $620.47 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $618.08 | 2020-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $603.26 | 2021-2025 | Sotyktu |
| Incyte Corporation | $574.57 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $508.29 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $393.46 | 2019-2025 | |
| Ucb, INC. | $373.95 | 2020-2025 | Bimzelx |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $369.73 | 2022-2024 | Vtama |
| Revance Therapeutics, INC. | $360.25 | 2024-2025 | Daxxify |
| Amgen INC. | $317.89 | 2019-2024 | Otezla |
| Merz North America, INC. | $244.33 | 2019-2022 | |
| Genentech USA, INC. | $193.95 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $193.19 | 2023-2025 | Zoryve |
| Biofrontera INC. | $183.94 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Dusa Pharmaceuticals, INC. | $171.15 | 2019 | |
| Almirall LLC | $156.05 | 2019-2025 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.51 | 2022-2023 | Spevigo |
| Janssen Scientific Affairs, LLC | $123.07 | 2021 | |
| Epi Health, LLC | $92.00 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $77.88 | 2019 | |
| Verrica Pharmaceuticals INC. | $62.34 | 2024-2025 | Ycanth |
| Mayne Pharma Commercial LLC | $61.22 | 2019-2020 | |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Botanix Sb INC | $47.28 | 2025 | Sofdra |
| Organon LLC | $44.38 | 2024-2025 | Vtama |
| Dermira, INC. | $25.76 | 2021 | |
| Organogenesis INC. | $23.59 | 2024 | Puraply Am |
| Polynovo North America LLC | $18.14 | 2024 | Novosorb Btm |
| Lnhc, INC | $14.50 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Boudreaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.